Latest News-Wuxi Biologics Mediaroom_Page

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2023-10-02 08:30 1393

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2023-08-11 08:30 4360

WuXi Biologics to Increase Manufacturing Capacity in Germany

- In response to global clients' increasing demand for contract manufacturing services, WuXi Biolo...

2023-06-01 16:49 3480

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading gl...

2023-05-22 16:30 2533

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-cl...

2023-05-16 16:00 2022

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10%...

2023-04-28 14:43 2955

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global...

2023-03-28 20:11 2224

WuXi Biologics Reports Remarkable 2022 Annual Results

Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to R...

2023-03-22 20:09 3140

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell ...

2023-01-05 08:30 4020

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Cont...

2022-12-16 08:44 2112

WuXi Biologics Provides Corporate Updates

SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Co...

2022-10-27 22:13 2566

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global ma...

2022-10-26 12:30 2117

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing g...

2022-10-24 08:30 2052

Latest News

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services

WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WuXi Biologics Reports Remarkable 2022 Annual Results

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

WuXi Biologics Provides Corporate Updates

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

WuXi Biologics Receives "Best CDMO Award of the Year"

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

WuXi Biologics Co., Ltd. Removed from Unverified List

WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey

WuXi Biologics Reports Strong 2022 Interim Results